Figure 7. C4-27z and C4opt-27z RNA CAR T cells reduce the progression of solid ovarian cancer in vivo.

A. NSG mice bearing solid SKOV3 tumor were treated with on intratumuoral injection of 2 × 10⁷ CAR+ T cells on day 21 (loading dose) followed by a lower maintenance dose of 10⁷ CAR+ T cells on days 28 and 35. B–C. Tumor growth was measured weekly by SKOV3 fLUC⁺ bioluminescence (B) and by caliper measurement. C4-27z and C4opt-27z CAR T lymphocytes treated significantly reduced tumor bioluminescence and volume compared to animals receiving no treatment (2-way ANOVA, p < .001). D. CD4⁺ and CD8⁺ C4-27z and C4opt-27z CAR T cells were initially present at low numbers in peripheral circulation, suggesting FRα-specific CAR T cell migration to specific tumor locales (student t test, p < .01 - .001). E. Repeat administration of C4-27z and C4opt-27z CAR T cells resulted in CD4⁺ and CD8⁺ T cell expansion in peripheral blood during therapy (student t test, p < .01 - .001) F. C4-27z and C4opt-27z CAR T cells are not eliminated after treatment and continue to proliferate despite losing CAR reactivity (student t test, p < .05 - .01).